French Regulator Fines Novo Nordisk and Eli Lilly Over Weight Loss Drug Ad Campaigns
France's National Agency for Medicines and Health Products Safety fined Novo Nordisk approximately $2 million for misleading advertisements for Wegovy and Saxenda, and fined Eli Lilly roughly $127,000 for Mounjaro advertising that constituted indirect promotion of a prescription-required medicine. The penalties reflect growing regulatory concern over potential misuse of weight loss medications.
French regulator fines
▪France's National Agency for Medicines and Health Products Safety fined Eli Lilly roughly $127,000 over advertising for Mounjaro obesity treatment that purportedly amounted to indirect promotion of a medicine for which a prescription is required.
▪France's National Agency for Medicines and Health Products Safety fined Novo Nordisk approximately $2 million for running misleading advertisements for Wegovy and Saxenda medications.
Weight loss drug advertising violations
▪Eli Lilly's advertising for Mounjaro obesity treatment purportedly amounted to indirect promotion of a medicine for which a prescription is required.
Regulatory scrutiny concerns
▪The penalties against Novo Nordisk and Eli Lilly reflect increasing concern among regulators that weight loss medicines may be misused.
▪Promotions run by pharmaceutical companies for weight loss medicines are being closely scrutinized by regulators.
▪France's National Agency for Medicines and Health Products Safety issued a bulletin on the risks associated with weight loss drugs in 2024, especially inappropriate use.
Perspective of Regulators (France's National Agency for Medicines and Health Products Safety)
▪France's National Agency for Medicines and Health Products Safety issued a bulletin on the risks associated with weight loss drugs in 2024, especially inappropriate use.
▪The penalties against Novo Nordisk and Eli Lilly reflect increasing concern among regulators that weight loss medicines may be misused.
Story comments
Loading comments…